NCT06153693Phase 3Completed

Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

Study sponsor: Mineralys Therapeutics Inc. · MLYS

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-12-10Actual
Enrollment · participants1083Actual
Source updated2026-05-01Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview